Physician profile
Chun Hwang
NPI 1649238080
$288,538.30
in general payments reported to CMS, 2019-2025
13 companies · $59K in 2025
The $59K reported for 2025 was more than what 96% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $42.30 · 2021: $368 · 2022: $2,524 · 2023: $102K · 2024: $124K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $196K · Travel and Lodging: $73K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $195,750.00 |
| Travel and Lodging | $73,390.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,444.00 |
| Food and Beverage | $1,698.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $270,562.11 | 2019-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit, Ensite Precision |
| Medtronic, INC. | $16,565.73 | 2023-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $616.62 | 2019-2024 | |
| Pfizer INC. | $232.85 | 2020-2022 | |
| Cardiofocus, INC. | $131.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $120.53 | 2019-2022 | |
| Biosense Webster, INC. | $114.07 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $67.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.36 | 2021-2022 | |
| Amgen INC. | $21.42 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $20.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.41 | 2021 | |
| Merck Sharp & Dohme LLC | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.